Trial ID or NCT#

NCT02003222

Status

RECRUITING

Purpose

This randomized phase III trial studies combination chemotherapy with blinatumomab to see how well it works compared to induction chemotherapy alone in treating patients with newly diagnosed breakpoint cluster region (BCR)-c-abl oncogene 1, non-receptor tyrosine kinase (ABL)-negative B lineage acute lymphoblastic leukemia. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as blinatumomab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread It is not yet known whether combination chemotherapy is more effective with or without blinatumomab in treating newly diagnosed acute lymphoblastic leukemia.

Official Title

A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults

Eligibility Criteria

Ages Eligible for Study: 30 Years to 70 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: Yes

Investigator(s)

Lauren Maeda
Medical oncologist, Hematologist, Lymphoma specialist
Clinical Assistant Professor, Medicine - Oncology Clinical Assistant Professor, Medicine - Hematology
Michaela Liedtke
Hematologist, Medical oncologist, Multiple myeloma specialist, Leukemia specialist
Associate Professor of Medicine (Hematology) at the Stanford University Medical Center
Caroline Berube
Hematologist
Clinical Associate Professor, Medicine - Hematology
Steven Coutre
Hematologist, Leukemia specialist
Professor of Medicine (Hematology) at the Stanford University Medical Center
Rondeep Brar
Hematologist, Leukemia specialist, Medical oncologist
Clinical Associate Professor, Medicine - Hematology

Contact us to find out if this trial is right for you.

CONTACT

Won W. Chang
(650) 736-8113